ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)
CUSIP: 00166B105
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 132,570,600
- Total 13F shares
- 48,509,608
- Share change
- +2,790,309
- Total reported value
- $292,389,850
- Put/Call ratio
- 27%
- Price per share
- $6.03
- Number of holders
- 107
- Value change
- -$2,826,841
- Number of buys
- 66
- Number of sells
- 50
Quarterly Holders Quick Answers
What is CUSIP 00166B105?
CUSIP 00166B105 identifies ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00166B105:
Top shareholders of ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| venBio Partners LLC |
13F
|
Company |
7.3%
|
9,699,925
|
$108,154,164 | — | 31 Mar 2024 | |
| FMR LLC |
13F
|
Company |
5.7%
|
7,522,812
|
$83,879,354 | — | 31 Mar 2024 | |
| LSV Associates, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,526,963
|
$61,575,751 | — | 13 Dec 2021 | |
| Redmile Group, LLC |
13F
|
Company |
3.3%
|
4,326,509
|
$48,240,575 | — | 31 Mar 2024 | |
| Vivo Capital, LLC |
13F
|
Company |
3.2%
|
4,220,048
|
$47,053,535 | — | 31 Mar 2024 | |
| Cormorant Asset Management, LP |
13F
|
Company |
2.4%
|
3,142,079
|
$35,034,181 | — | 31 Mar 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
2.1%
|
2,717,970
|
$30,305,366 | — | 31 Mar 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
2%
|
2,610,000
|
$29,101,500 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
1.7%
|
2,221,561
|
$24,770,406 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.2%
|
1,566,464
|
$17,466,072 | — | 31 Mar 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
0.96%
|
1,268,471
|
$14,143,452 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.93%
|
1,235,215
|
$13,772,647 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.46%
|
604,714
|
$6,743,426 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.42%
|
553,867
|
$6,175,617 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.26%
|
343,137
|
$3,825,977 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.18%
|
245,212
|
$2,734,114 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.18%
|
234,100
|
$2,610,000 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.18%
|
232,769
|
$2,596,000 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.16%
|
209,759
|
$2,338,813 | — | 31 Mar 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.15%
|
201,362
|
$2,245,187 | — | 31 Mar 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.12%
|
160,000
|
$1,784,000 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.12%
|
157,002
|
$1,750,572 | — | 31 Mar 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.1%
|
127,037
|
$1,416,463 | — | 31 Mar 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.09%
|
121,546
|
$1,355,238 | — | 31 Mar 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.08%
|
106,356
|
$1,185,869 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.08%
|
105,894
|
$1,180,718 | — | 31 Mar 2024 | |
| LOS ANGELES CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.07%
|
98,960
|
$1,103,404 | — | 31 Mar 2024 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.07%
|
90,957
|
$1,014,171 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.06%
|
79,767
|
$889,402 | — | 31 Mar 2024 | |
| Aberdeen Group plc |
13F
|
Company |
0.05%
|
66,211
|
$738,253 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.05%
|
65,455
|
$729,823 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.05%
|
60,190
|
$671,119 | — | 31 Mar 2024 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.05%
|
60,119
|
$670,327 | — | 31 Mar 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.04%
|
59,195
|
$660,024 | — | 31 Mar 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.04%
|
59,186
|
$659,000 | — | 31 Mar 2024 | |
| STATE OF WISCONSIN INVESTMENT BOARD |
13F
|
Company |
0.04%
|
54,366
|
$606,181 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.04%
|
50,341
|
$561,303 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.04%
|
49,860
|
$555,931 | — | 31 Mar 2024 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.04%
|
49,000
|
$546,350 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.04%
|
47,155
|
$525,779 | — | 31 Mar 2024 | |
| Swiss National Bank |
13F
|
Company |
0.03%
|
44,200
|
$492,830 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.03%
|
43,507
|
$485,103 | — | 31 Mar 2024 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.03%
|
41,000
|
$468,000 | — | 31 Mar 2024 | |
| Nan Fung Group Holdings Ltd |
13F
|
Company |
0.03%
|
41,950
|
$467,743 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.03%
|
41,897
|
$467,152 | — | 31 Mar 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.03%
|
38,790
|
$432,509 | — | 31 Mar 2024 | |
| Walleye Capital LLC |
13F
|
Company |
0.03%
|
38,241
|
$426,387 | — | 31 Mar 2024 | |
| MARTINGALE ASSET MANAGEMENT L P |
13F
|
Company |
0.03%
|
36,195
|
$403,575 | — | 31 Mar 2024 | |
| Inspire Investing, LLC |
13F
|
Company |
0.03%
|
33,156
|
$369,689 | — | 31 Mar 2024 | |
| Financial Advisory Group |
13F
|
Company |
0.02%
|
31,417
|
$350,300 | — | 31 Mar 2024 |
Institutional Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q2 2024
As of 30 Jun 2024,
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) was held by
107 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,509,608 shares.
The largest 10 holders included
venBio Partners LLC, FMR LLC, Vivo Capital, LLC, Redmile Group, LLC, Vestal Point Capital, LP, BlackRock Inc., MPM BIOIMPACT LLC, ORBIMED ADVISORS LLC, VANGUARD GROUP INC, and Paradigm Biocapital Advisors LP.
This page lists
108
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
105
Q2 2024 holders
107
Holder diff
2
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.